Asset Details
Do you wish to reserve the book?
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Do you wish to request the book?
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
2016
Overview
The addition of the oral proteasome inhibitor ixazomib to a regimen of lenalidomide plus dexamethasone led to a significant prolongation of progression-free survival of almost 6 months, as compared with placebo, with a small increase in the risk of thrombocytopenia.
Outcomes of multiple myeloma have improved substantially over the past 15 years with the introduction of proteasome inhibitors and immunomodulatory drugs,
1
,
2
and these agents now form the backbone of therapy for multiple myeloma.
3
In phase 3 studies, triplet regimens based on these agents were shown to be more efficacious than doublet regimens when these regimens were used as a first-line treatment
4
–
6
and in relapsed disease.
7
,
8
In addition, there has been a shift in treatment patterns toward the use of extended treatment to further improve long-term outcomes,
9
and this shift highlights the need for additional effective agents with . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Boron Compounds - administration & dosage
/ Boron Compounds - adverse effects
/ Dexamethasone - administration & dosage
/ Exanthema - chemically induced
/ Glycine - administration & dosage
/ Glycine - analogs & derivatives
/ Humans
/ Male
/ Multiple Myeloma - drug therapy
/ Patients
/ Steroids
/ Survival
/ Thalidomide - administration & dosage
